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Abstract
Local immunotherapies are under investigation for treatment of unresectable tumors and sites of solid
tumor resection to prevent local recurrence. Successful local therapy could also theoretically elicit
systemic immune responses against cancer. Here we explored the delivery of therapeutic dendritic
cells (DCs), cytokines, or other immunostimulatory factors to tumors via the use of ‘self-gelling’
hydrogels based on the polysaccharide alginate, injected peritumorally around established melanoma
lesions. Peritumoral injection of alginate matrices loaded with DCs and/or an interleukin-15
superagonist (IL-15SA) around 14-day established ova-expressing B16F0 murine melanoma tumors
promoted immune cell accumulation in the peritumoral matrix, and matrix infiltration correlated with
tumor infiltration by leukocytes. Single injections of IL-15SA-carrying gels concentrated the
cytokine in the tumor site ~40-fold compared to systemic injection and enabled a majority of treated
animals to suppress tumor growth for a week or more. Further, we found that single injections of
alginate matrices loaded with IL-15SA and the Toll-like receptor ligand CpG or two injections of
gels carrying IL-15SA alone could elicit comparable anti-tumor activity without the need for
exogenous DCs. Thus, injectable alginate gels offer an attractive platform for local tumor
immunotherapy and facilitates combinatorial treatments designed to promote immune responses
locally at a tumor site while limiting systemic exposure to potent immunomodulatory factors.
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Introduction
Localized cancer therapies are utilized to treat unresectable tumors and/or for treating sites of
surgical resection to combat local recurrence [1–3]. Immunotherapy treatments delivered
directly at solid tumor sites have been explored with the goal of utilizing the tumor itself as a
source of tumor antigens to generate a systemic immune response that could eliminate distal
metastases. Most immunotherapy strategies seek to promote the robust infiltration of tumors
with functional immune cells to promote tumor destruction, but defects in tumor vasculature,
suppressive signals produced by tumor cells or co-opted tumor-resident immune cells, and
rapid tumor growth can limit the accumulation of activated and competent immune cells [4,
5]. Recently, combinations of cytokine, chemotherapy, and/or immunostimulatory ligand
treatments used to locally treat established tumors have shown promise in not only eliminating
treated tumors but also generating systemic immunity [6–11]. However, such potent
immunostimulatory regimens can elicit serious toxicity and may need to be coupled with
methods to control delivery and limit systemic exposure [12,13]. Prior work has demonstrated
that controlled release of immunocytokines from gels or microparticles at a tumor site can
enhance local immunotherapies, by sustaining the intratumoral concentration of these factors
while reducing systemic exposure following a single injection [14–16]. Thus, the use of
biomaterials to deliver local combinatorial immunotherapies may lead to further enhancements
in the potency and safety of local immunotherapy.
We recently described an injectable gel formulation of the polysaccharide alginate, which can
be loaded with exogenous immune cells, proteins, or immunoregulatory factors [17,18].
Alginate has been studied extensively as a matrix for cell therapy and tissue engineering, and
has been shown to be safe for use in humans [19–21]. We found that injection of alginate gels
with embedded activated dendritic cells in healthy mice elicits a sustained infiltration of host
T-cells and dendritic cells into the matrix, and that these matrices can release encapsulated
cytokines over a period of 7–14 days [17,18]. We hypothesized that a similar recruitment of
lymphocytes and DCs to alginate gels surrounding established tumors could promote local
antigen presentation, and provide a local reservoir of immune cells for tumor invasion. To test
this concept, in the present study we surrounded established melanoma tumors with DC/
cytokine/Toll-like receptor (TLR) ligand-loaded gels, and analyzed tumor growth and the
recruitment of leukocytes to the tumor-engulfing gels and the tumors themselves. Because
these gels were stable at least one month in vivo they were readily recovered post-treatment,
and thus we also analyzed the composition of innate and adaptive immune cells recruited to
both the gels and the tumor itself following peritumoral gel therapy.
Materials and Methods
Materials
Sterile alginates Pronova SLM20 (MW 75,000–220,000 g/mol, >50% M units) and Pronova
SLG20 (MW 75,000–220,000 g/mol, >60% G units) were purchased from Novamatrix (FMC
Biopolymers, Sandvika, Norway). Anti-mouse FITC-TCRβ, anti-mouse PE-I-Ab, anti-mouse
APC-CD11c, anti-mouse APC-CD8α, anti-mouse APC-CD4, anti-moue FITC- and PE-NK1.1
were purchased from BD Biosciences (San Jose, CA). APC-tetramer ova-MHC I was from
Beckman Coulter (Fullerton, CA), anti-mouse PE-CD8α antibody was from Invitrogen (San
Diego, CA), and anti-mouse foxp3 staining kit was from eBioscience (San Diego, CA).
Isooctane was obtained from Mallinckrodt Baker (Phillipsburg, NJ). Calcium chloride
dihydrate and alginate lyase were from Sigma-Aldrich (St. Louis, MO). CpG oligonucleotides
with a phosphorothioate backbone (CpG 1826, sequence 5′-/5AmMC6/
TCCATGACGTTCCTGACGTT-3′) were synthesized by Integrated DNA Technologies.
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Mouse IL-15 and mouse IL-15Rα-human Fc chimera recombinant proteins and ELISA
detection kits were purchased from R&D Systems (Minneapolis, MN).
Animals and cells
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state, local
and NIH guidelines for animal care. C57Bl/6 mice were obtained from the Jackson Laboratory.
Bone marrow-derived dendritic cells were prepared following a modification of the procedure
of Inaba [22] as previously reported [23]. DCs were activated/matured with 1μM CpG and
pulsed with 1 μg/mL each of ova class I and ova class II peptides (Anaspec, San Jose, CA) for
18 hrs and washed 3X with PBS before use. B16F10 parental melanoma cells were obtained
from American Type Culture Collection. B16-ova cells based on the B16F0 parental melanoma
line were transfected with ovalbumin expressed as an MSCV vector with puromycin resistance,
followed by an IRES and Ovalbumin-2A-green fluorescent protein (GFP). The ova expressed
in these cells lacks the first 55 amino acids (deleting the secretion signal) and is soluble in the
cytoplasm.
Tumor inoculation and alginate gel therapy
Except where noted otherwise, anesthetized C57Bl/6 mice were inoculated with 3×104 B16-
ova cells s.c., which were allowed to establish for 14 days. IL-15 superagonist (IL-15SA) was
prepared by incubating 5 μg IL-15 and 31.7 μg IL-15Ra/Fc (equimolar amounts) at 37°C in
15.9 μL PBS for 30 min. Matrix alginate (160 μL of 0.01 g/mL SLM20 alginate in sterile PBS
at 4°C) was mixed with factors to be delivered (e.g., 2×106 dendritic cells, 36.7 μg IL-15 SA,
and/or 80μg CpG in 150 μL gel) and kept on ice until injection. Calcium-loaded alginate
microspheres were synthesized as previously described [17,18]. Endotoxin levels in the
alginate preparations were well below levels stimulatory for innate immune cells [24], as
described previously [18]. The Calcium-loaded microspheres (~1×106) were mixed with the
matrix alginate solution and 150 μL of the mixture immediately injected s.c., surrounding
tumors. For i.p. injections, 36.7 μg of IL-15SA was injected in 200 μL of PBS, and for i.t.
injections, the same amount of IL-15SA and 2 × 106 dendritic cells were injected into tumors
in 30μL of PBS.
Flow cytometry analysis
Alginate gels, lymph nodes, and spleens recovered from treated animals were digested with
0.28 WÜ/mL Liberase Blendzyme 3 (Roche Applied Sciences, Indianapolis, IN) and 1 mg/
mL of alginate lyase (Sigma) for 20 min at 37°C. Digested gels and tissues were passed through
a 40 μm nylon mesh cell strainer (BD Falcon) with 9 mL complete RPMI medium. Recovered
cells were resuspended in FACS buffer (1% BSA, 0.1% NaN3 in Hank’s balanced salt solution,
pH 7.4) at 4°C, blocked with anti-CD16/32 antibody for 10 min, then stained with fluorescent
antibodies for 20 min on ice, followed by 3 washes with FACS buffer and addition of 1.25μg/
mL propidium iodide (PI) for viability assessment. For foxp3 staining, cells were fixed,
permealized, and stained according to the manufacturer’s instructions. Stained cells were
analyzed on a BD FACSCalibur flow cytometer. Enumeration of cellular infiltrates was
performed by calibration of flow cytometer events to cell suspensions of known concentration,
and cell frequencies determined from a live cell gate with low PI staining. Cell losses during
the multiple wash/treatment steps of gel and tissue digestions were reproducible and were
accounted for in the reported recovered cell numbers.
IL-15SA release in vitro and in vivo
Soluble IL-15Rα/Fc (15.9 μg, 2 mg/mL in PBS) was mixed with 80 μL of alginate matrix
solution (0.01g/mL in PBS), and then gelled with 5×105 calcium-loaded alginate microspheres
to crosslink the alginate in an epppendorf tube for 2 hrs at 37 °C. RPMI medium with 10%
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FCS was added (500 μL) and cytokine release was assessed by ELISA analysis quantifying
IL-15Rα in the supernatant at staggered time points. The release of the IL-15SA was quantified
in vivo by injecting alginate gels carrying 36.7 μg IL-15SA (31.7 μg IL-15Rα-Fc + 5 μg IL-15)
around 14 day-old B16-ova tumors in C57Bl/6 mice. Gels and tumors were recovered from
independent mice at staggered times, digested using the protocol described above, or by using
T-Per Tissue Protein Extraction Reagent (Pierce, Rockford, IL) supplemented by Halt Protease
Inhibitor Cocktail (Pierce) according to the manufacturer’s instructions. The digestion
supernatants were collected and the amount of IL-15SA was quantified by using IL-15Rα
ELISA kit or two-site IL-15Rα/IL-15 ELISA. IL-15 loss due to the digestion process was
analyzed using control digestions using known quantities of IL-15SA and were accounted for
in the analysis.
Statistical Analysis
All data are shown as mean±S.E. Comparisons of two experimental groups were performed
using two-tailed Mann-Whitney tests. Comparisons of Kaplan-Meier survival curves were
made using a log-rank test.
Results
T-cell recruitment to tumor-surrounding gels
We recently developed an injectable self-gelling formulation of the polysaccharide alginate,
obtained by mixing calcium-loaded alginate microspheres with an alginate solution just prior
to injection [17,18]. Upon injection, calcium ions from the microspheres and the surrounding
interstitial fluid diffuse into the alginate solution and ionically crosslink the polysaccharide
chains in situ, enabling gelation in < 60 min in vivo. The resulting soft gels retain more than
80% of their original mass for ~30 days in vivo, and can entrap co-injected cells or cytokines
for slow release into the local environment [17,18]. In our previous study in healthy animals
[17], we showed that s.c. injection of alginate gels carrying activated, antigen-loaded dendritic
cells (DCs) elicited priming of naïve CD8+ T-cells in the local draining lymph nodes (supported
by migration of a small number of DCs from the gel to the lymph nodes), followed by trafficking
of primed antigen-specific T-cells to the gels. To determine whether DCs delivered in alginate
gels could similarly promote accumulation of antigen-specific T-cells at solid tumor sites, we
analyzed the response of established melanoma tumors to locally-injected DC-carrying gels.
We generated a model system where B16F0 melanoma cells were transfected with green
fluorescent protein (GFP) and ovalbumin to enable visualization of antigen capture by dendritic
cells and tracking of the immune response to a defined antigen, respectively. We first analyzed
the response of established GFP/ova-expressing B16F0 (hereafter designated B16-ova) tumors
to peritumoral injections of DCs in alginate gels. B16-ova cells were inoculated s.c. in C57Bl/
6 recipients and allowed to establish for 7 or 14 days. Mice then received a single injection of
alginate (150 μL) to surround tumors with gels carrying activated bone marrow-derived
dendritic cells loaded with immunodominant class I- and class II-restricted ova peptides (Fig.
1A). Tumor growth was monitored and gels were recovered 14 days after injection for digestion
and analysis of the local immune cell infiltrate accumulating at the tumor site. As shown in
Fig. 1B, “empty” alginate gels injected around 14-day-old tumors contained few CD4+ or
CD8+ T-cells. In contrast, gels carrying ova-pulsed, activated DCs elicited a substantial
accumulation of CD4+ T-cells. However, in contrast to responses in healthy mice [17], DC-
loaded gels did not recruit many CD8+ T-cells or endogenous ova-specific CD8+ T-cells to the
peritumoral matrix (Fig. 1B). Further, the net therapeutic effect of this CD4+-rich T-cell
recruitment to the tumor-surrounding gels was limited: DC-carrying gels elicited a minor
suppression of 7-day established melanomas (which did not reach statistical significance) and
were ineffective for treating 14-day established tumors (Fig. 1C). Thus, peritumoral gels
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carrying activated DCs supported the recruitment of CD4+ T-cells to the matrix, but attraction
of CD8+ T-cells was poor and the effect on established tumor growth was limited.
IL-15SA release from alginate gels
We hypothesized that the poor therapeutic effect of DC delivery in tumor-surrounding gels
reflected insufficient recruitment of CD8+ T-cells (or other immune effector cells such as
natural killer cells) to the matrices and/or suppression of recruited immune cell function at the
tumor site. Thus, we next tested the ability of alginate gels to carry both DCs and
immunocytokines, for slow release of signals that would support CD8+ T-cell accumulation
and sustained effector functions in the tumor-local environment. Recent studies have
demonstrated that interleukin-15 (IL-15) is capable of reverting the anergic state of tumor-
infiltrating T-cells [25,26]. In addition, it has been shown that mixtures of IL-15 with a
recombinant soluble form of the IL-15 receptorα chain form long-lived complexes that function
as an IL-15 superagonist (IL-15SA). These complexes potently expand CD8+ T-cell, natural
killer (NK) cell, and NK T-cell populations in vivo [25,27–29]. Motivated by these prior
studies, we mixed pre-formed complexes of IL-15 and recombinant murine IL-15Rα-Fc fusion
protein (referred to hereafter as IL-15SA) with alginate solutions prior to gelation, to obtain
sustained release of this cytokine into the tumor environment. Self-gelled alginate released
encapsulated IL-15SA over ~2 weeks in vitro (Fig. 2A). In vivo, IL-15SA-loaded alginate gels
injected peritumorally around 14 day-old B16-ova tumors released cytokine for ~5–7 days
(Fig. 2B). In agreement with prior studies of local cytokine delivery [14,30], the level of
cytokine detected in the systemic circulation following tumor-local gel release was
substantially lower than levels achieved for the same total quantity of cytokine injected as a
bolus i.p., particularly over the first 4 days following injection (Fig. 2C). In addition, local
release of IL-15SA from peritumoral matrices led to peak concentrations of cytokine in the
tumor on day 3 post injection that were ~40-fold greater than that achieved by systemic cytokine
injection (Fig. 2D). Thus, IL-15SA delivered locally from peritumoral alginate ECMs lowered
systemic exposure to the cytokine and greatly concentrated the dose achieved within the tumor
itself compared to systemic injections.
Anti-tumor effects of Il-15SA-loaded alginate
To test the therapeutic effect of combining DCs and IL-15SA in tumor-surrounding matrices,
14-day established B16-ova tumors were treated with a single peritumoral injection of alginate
matrices carrying ova-pulsed dendritic cells and IL-15SA, and tumor growth was monitored
for 21 days. Compared to untreated controls, a single peritumoral immunization with alginate
carrying DCs and IL-15SA substantially retarded tumor growth in the majority of animals, and
enabled mice with tumors smaller than ~50 mm2 at the time of treatment to control tumor
growth for at least 1 week following gel injection (Fig. 3A). Larger tumors also occasionally
showed substantial reductions in size transiently following injection of alginate ECMs (Fig.
3A). Surprisingly, comparison of mean tumor sizes in mice receiving gels with DCs+IL-15SA
vs. IL-15SA alone showed that the cytokine played a dominant role in this combination
treatment, with DCs providing only a minor enhancement of the anti-tumor response (Fig. 3B).
Control of tumor growth required that IL-15SA was released locally from the peritumoral
matrix, as gels carrying DCs and IL-15SA injected on the flank opposite tumors or delivery of
IL-15SA via i.p. injection rather than locally from the gel had a much weaker anti-tumor effect
than injection of the cytokine-loaded synthetic ECMs around tumors (Fig. 3C). Further, DCs
and IL-15SA delivered in tumor-surrounding alginate gels were more effective than
intratumoral (i.t.) injection of DCs and IL-15SA in the absence of the alginate matrix (Fig. 3C).
Control of tumor growth elicited by DC/IL-15SA-carrying gels at the tumor site was reflected
in improved survival compared to each of these alternative treatments (Fig. 3D and data not
shown).
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To begin to understand how IL-15SA boosted the anti-tumor response elicited by tumor-
surrounding alginate ECMs, we analyzed the impact of IL-15SA delivery on the recruitment
of T cells at the tumor site following treatment of 14-day-established B16-ova tumors. As
shown in Fig.s 4A-C, single peritumoral injections of alginate carrying DCs and IL-15SA
increased the frequency but not the absolute number of CD4+ T-cells localizing in tumor-
surrounding alginate matrices compared to gels carrying DCs alone, but did amplify
accumulation of CD8+ T-cells by ~4-fold. Importantly, this CD8+ T-cell infiltrate included a
population of tumor antigen-specific cells detected by ova peptide-H-2Kb MHC tetramer
staining (Fig. 4D). Thus, colocalization of dendritic cells and IL-15SA in alginate gels around
B16-ova tumors suppressed the growth of large established tumors for up to a week, and this
anti-tumor response correlated with enhanced accumulation of CD8+ T-cells in the tumor-
surrounding gels.
Peritumoral delivery of IL-15SA and/or Toll-like receptor ligands from gels without dendritic
cells
Because preparation of autologous DCs is a laborious and costly process for clinical
implementation, we next tested whether cytokine or immunoregulatory factors alone could
achieve results equivalent to tumors treated with DCs+IL-15SA. We tested two alternatives:
first, providing two injections of alginate gel carrying IL-15SA alone, given peritumorally on
days 14 and 21; second, giving a single injection of alginate carrying both IL-15SA and the
Toll-like receptor-9 agonist CpG [9]. Testing IL-15SA alone was motivated by the strong anti-
tumor effect elicited by IL-15SA alone following single injections (Fig. 3B), and we
hypothesized that CpG might promote the activation and recruitment of local host dendritic
cells [9,31,32], to replace the need for exogenous DCs in the gels. As shown in Fig. 5A, mice
with day 14 B16-ova tumors receiving two injections of alginate loaded with IL-15SA
impressively halted/regressed tumors compared to untreated animals. When compared in the
same experiment, the average suppression of tumor growth seen for mice receiving a single
injection of alginate carrying DCs+IL-15SA was equivalent to that obtained for a single
injection of alginate gels carrying IL-15SA+CpG or two injections of alginate loaded with
IL-15SA alone (Fig. 5B). This was also reflected in enhanced survival of mice treated with
alginate carrying IL-15SA+CpG or two injections of alginate loaded with IL-15SA alone (Fig.
5C). Thus, optimal selection of immune-supporting factors for release from the peritumoral
matrix enables gel-based delivery to provide prolonged control of tumor growth without the
need for transfer of autologous DCs.
All of the experiments to this point involved melanoma tumor cells transduced with two
different foreign antigens (ova and GFP), which could increase tumor immunogenicity and
make the resulting tumors more readily rejected. We thus also tested whether 2 injections of
alginate loaded with IL-15SA could halt the growth of unmanipulated B16F10 tumors, which
are an accepted highly aggressive, poorly immunogenic melanoma. Because these parental
B16 tumors grew more quickly than B16-ova tumors, they were treated with alginate on days
11 and 18 to treat them at comparable initial tumor sizes as in the experiments with B16-ova.
As shown in Fig. 5D and E, treatment of B16F10 tumors with IL-15SA-loaded alginate gels
also halted growth of B16 tumors and greatly enhanced survival of treated mice.
To understand the relationship between attraction of immune cells to the tumor-surrounding
alginate gels and infiltration of the tumor itself, we next examined the cellular composition of
the local immune response in gels and their associated tumors when 14-day-old B16-ova
tumors were treated with two injections of IL-15SA-loaded alginate gels, analyzed 14 days
after the first gel injection (d28). Enumerating the frequency of CD4+ and CD8+ T-cells in
both the alginate matrix and tumors recovered from mice with a range of tumor burdens on
day 28, we found a strong correlation between the frequencies of CD4+ and CD8+ T-cells
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accumulated in peritumoral matrices vs. within the tumor itself (Fig. 6A). In a similar manner,
increased frequencies of CD11c+I-Ab+ dendritic cells (DCs) and NK1.1+ natural killer cells in
the alginate gels coincided with increased frequencies of these cells within tumors (Fig. 6B,
C). These results suggest that immune cell attraction to the peritumoral matrix either directly
promoted infiltration of the tumor itself or served as a surrogate indicator of conditions favoring
immune cell accumulation in tumors. As expected, infiltration of gels/tumors correlated with
smaller final tumor sizes (data not shown).
Finally, we extended our previous analysis of cellular infiltrates accumulating in the tumor-
surrounding gels for the case of mice that received two injections of IL-15SA-loaded alginate,
and examined regulatory T-cells and innate immune cells accumulating in the gels and tumors.
Untreated tumors were infiltrated by low frequencies of CD4+ cells, and 30–50% of these cells
were foxp3+, a marker of immunosuppressive regulatory T-cells (Fig. 7A). In response to
IL-15SA/gel therapy, both the frequency of foxp3+ cells (Fig. 7B) and the ratio of foxp3+ T-
cells to total T-cells [33] within tumors (Fig. 7C) were significantly reduced. In addition, the
frequencies of intratumoral NK cells and DCs were increased 16- and 4-fold respectively for
IL-15SA/gel-treated tumors compared to untreated controls (Fig. 7D, F). Treated mice showed
a trend (which did not reach statistical significance) of increased numbers of GFP+ host DCs
infiltrating the alginate gels, suggesting that active acquisition of tumor antigen was occurring
in the peritumoral matrices (Fig. 7E). Thus, immunotherapy with IL-15SA-loaded gels
enhanced CD8+ T-cell recruitment to the tumor site, lowered the relative frequency of
regulatory T-cells, and enhanced the frequency of innate immune cells, all factors expected to
augment the anti-tumor response.
Discussion
Immune responses to tumors are limited by a number of factors developing systemically and
at the tumor site directly. Two limitations in the anti-tumor immune response are insufficient
recruitment of T-cells to tumors [34–36] and loss of T-cell and innate effector cell functions
in the tumor microenvironment, either due to suppressive factors produced in the tumor site or
via the action of regulatory T-cells [37–39]. Complementary to many traditional
immunotherapy treatments being studied to overcome these challenges, biomaterials are
beginning to be explored as delivery vehicles to alter/augment anti-tumor immune responses,
both for parenteral delivery of anti-tumor vaccines [40,41] and for delivery of
immunotherapeutics directly at tumor sites [6–11].
In an attempt to both stimulate T-cells and overcome immunosuppression at the tumor site, we
investigated local tumor immunotherapy achieved by engulfing established tumors with
injectable synthetic ECMs carrying antigen-pulsed dendritic cells or immunoregulatory
cytokines. The use of the biopolymer alginate in these studies was motivated by its known
biocompatibility and extensive track record in cell transplantation and tissue engineering
applications [19–21,42]. We previously demonstrated an injectable self-gelling formulation of
alginate obtained by mixing calcium-alginate microspheres with an alginate solution, which
crosslinked to form a soft gel in vivo via redistribution of calcium from the microspheres into
the surrounding alginate solution and diffusion of calcium from the interstitial fluid into the
alginate matrix [17,18]. Alginate gels loaded with activated dendritic cells and injected s.c. in
healthy mice elicited robust recruitment of T-cells to the gels, and DCs loaded with specific
peptide antigens recruited antigen-specific T-cells into the gels [17].
Here we explored use of this synthetic ECM as a carrier for tumor-local delivery of dendritic
cells and immunoregulatory factors, particularly IL-15 in a superagonist form. DCs have been
examined in preclinical and clinical studies as possible cell-based cancer therapeutics capable
of breaking tolerance to tumors [43–45], while IL-15 has been reported to trigger proliferation
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of anergic tumor-infiltrating T-cells [26] and revive effector functions of tumor-resident T-
cells [25]. Superagonist IL-15 formed by complexing IL-15 with a recombinant soluble form
of its high-affinity IL-15Rα chain has been shown to expand CD8+ T-cells, NK cells, and NK
T-cells in vivo more effectively than IL-15 alone [27,28], and repeated systemic injections of
IL-15SA have been shown to slow tumor growth in vivo [25]. IL-15 can also induce
differentiation of monocytes into Langerhans Cell-like IL-15 DCs [46], and plays a role in
maximizing APC function [47]. We hypothesized that by surrounding tumors with DC/
IL-15SA-loaded gels, leukocyte accumulation would be elevated and IL-15SA would be
concentrated at the tumor site over several days, while systemic exposure to the cytokine would
be reduced.
Prophylactic immunization in murine models has often been found to elicit protective immunity
that can reject subsequent tumor challenges, but elimination of solid tumors that have grown
for a week or more and have an established blood supply (the situation of most relevance to
human cancer therapy) is a much more difficult challenge for immunotherapy strategies. Using
a melanoma model, we found that activated, antigen-loaded DCs alone in peritumoral alginate
ECMs were unable to slow established melanoma tumor growth. In contrast to gels carrying
DCs alone, DCs combined with IL-15SA in gels elicited anti-tumor responses that could control
established melanomas for up to a week following a single injection, and enhanced survival of
treated animals (Fig. 3). This optimal therapeutic response from a single injection was achieved
only when IL-15SA was provided locally at the tumor site and slow-released from the tumor-
surrounding matrix. Notably, exogenous DCs could be excluded from the therapy by either
providing repeated IL-15SA/gel injections or by combining IL-15SA with Toll-like receptor
ligands for slow release in the tumor environment, substantially simplifying this approach from
a clinical standpoint.
As a first step toward understanding how gel-mediated cytokine/DC delivery enhanced the
anti-tumor immune response, we sought to analyze the composition of immune cells
accumulating in gels and tumors. To this end, alginate matrices simultaneously served as stable
surrogate ECMs surrounding the tumor site, facilitating characterization of the immune
response developing following tumor cell inoculation and immunotherapy. We found that DCs
alone in peritumoral alginate ECMs attracted CD4+ T-cells to tumor sites but elicited weak
CD8+ T-cell recruitment and had a very limited therapeutic effect on established B16-ova
tumors. However, IL-15SA delivery in the presence or absence of DCs increased the numbers
of CD8+ T-cells within alginate matrices (Fig. 5B and data not shown), and increasing
peritumoral accumulation of T-cells correlated with increased frequencies of lymphocytes
within tumors (Fig. 6). In prior studies where IL-15SA was used as a stand-alone therapy for
treatment of pancreatic tumors by repeated systemic injection, the enhanced anti-tumor
response appeared to be driven by rescued CD8+ T-cells already resident with tumors rather
than by recruitment of new T-cells to the tumor site [25]. Here we found that when IL-15SA
was released locally at the tumor site over several days from the alginate matrix (alone or with
DCs), the cytokine promoted accumulation of T-cells in both the peritumoral matrix and tumor,
and reduced the relative frequency of foxp3+ Tregs. Whether these accumulating T-cells were
expanding lymphocytes already resident in tumors at the time of treatment or represented cells
recruited to the site following gel therapy remains to be determined.
Conclusions
The ultimate goal of local immunotherapy is the generation of a systemic immune response
capable of eliminating disseminated tumors and distant metastases following treatment of an
accessible tumor site, and several recent reports provide evidence that this may be possible.
The studies reported here suggest that injectable alginate matrices may be useful materials for
tumor-local delivery of IL-15SA or other immunostimulatory factors, while importantly
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providing a means to lower systemic exposure and frequency of dosing of these potent and
potentially toxic factors. The ability of tumor-surrounding gels to concentrate
immunoregulatory factors in neighboring tumors over several days should simultaneously
maximize the therapeutic effect on nascent immune responses generated directly at tumor sites.
Successful local immune responses might enable the transformation of treated tumors from
growing malignancies into in situ vaccines that trigger systemic immunity.
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Fig. 1. Alginate gels carrying dendritic cells alone have minimal efficacy against established
melanoma tumors
(A) Schematic of therapeutic approach. (B–D) C57Bl/6 mice were inoculated with 5×104 B16-
ova tumor cells, and 7 or 14 days later, mice received a single peritumoral injection of either
empty self-gelling alginate matrices or alginate carrying 2×106 activated, ova peptide-loaded
DCs. (B) Numbers of gel-infiltrating T-cells recovered 14 days after injections (n = 4 mice per
group, bars: s.e.m.). (C, D) B16-ova tumor growth following treatment of 7-day- (C) or 14-
day- (D) established tumors with alginate gels alone (▽) or alginate loaded with antigen-pulsed
DCs (◆) compared to untreated tumors (○) (n = 4 mice per group). P values shown relative
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to untreated control. Data shown are representative from 1 of 2 independent experiments. (error
bars: s.e.m.)
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Fig. 2. IL-15SA delivered via alginate matrices concentrates cytokine in the tumor and lowers
systemic exposure relative to systemic injection
(A) 16 μg IL-15Rα/Fc was mixed with 80 μL self-gelling alginate in vitro and release into
medium at 37°C was measured over 2 weeks by ELISA. (Shown is 1 of 2 independent
experiments). (B–D) 36.7 μg IL-15SA (5 μg IL-15 + 31.7 μg IL-15Rα/Fc, equimolar) was
mixed with 150 μL self-gelling alginate and injected peritumorally around 14-day-old B16-
ova tumors (○). For comparison, the same quantity of IL-15SA (in PBS) was injected i.p. as a
separate group (■). Cytokine present in the gels (B), serum (C), and tumor itself (D) was
monitored by ELISA over 7–10 days (n = 4 samples per time-point). Inset of (C) shows the
integrated area under the curve quantifying total cytokine exposure in serum for gel vs. i.p.
delivery of IL-15SA over the 10 day timecourse. * in C: P = 0.05 (one-tailed) compared to i.p.
injection; * in D: P = 0.05 compared to i.p. injection. Data shown in B–D are from 1 of 2
independent experiments. (error bars: s.e.m.)
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Fig. 3. Dendritic cells combined with IL-15SA in alginate matrices elicit prolonged control of tumor
growth
Established B16-ova tumors were left untreated or received peritumoral injections of alginate
gels carrying antigen-pulsed DCs and/or IL-15SA (n = 10 per group). (A) Tumor growth curves
are shown for untreated mice or mice treated with alginate carrying DCs+IL-15SA. (B)
Average tumor growth for mice treated with alginate carrying DCs+IL-15SA (■) or IL-15SA
alone in gels (✱), or left untreated (○). (C) Tumor growth for untreated mice (○) vs. mice treated
with alginate carrying DCs+IL-15SA (■), intratumoral injection of DCs and IL-15SA in PBS
(●), s.c. injection of alginate carrying DCs and IL-15SA on flank opposite from the tumor
(◇), or peritumoral injection of alginate carrying DCs while IL-15SA is given i.p. (□). (D)
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Survival of mice treated with alginate carrying DCs+IL-15SA (■), intratumoral injection of
DCs+IL-15SA (●), or left untreated (○). Shown are representative data from 1 of 2 independent
experiments. (error bars: s.e.m.; P values: comparison to untreated controls)
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Fig. 4. Alginate gels carrying IL-15SA elicit accumulation of CD8+ T-cells in the matrix
Established B16-ova tumors were treated on d14 by peritumoral injection of empty alginate
gels or gels carrying antigen-pulsed DCs and/or IL-15SA (n = 4–5 per group). Gels were
recovered on d28 for analysis. (A) Representative flow cytometry analyses (CD8 vs T cell
receptor) of T-cell infiltration in gels. Mean numbers of CD4+ (B) CD8+ (C), and antigen-
specific ova tetramer-stained T-cells recovered from gels (D) show increase in the number of
CD8+ and antigen-specific T cells at the tumor microenvironment upon addition of IL-15SA.
(error bars: s.e.m.)
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Fig. 5. Single peritumoral injections of alginate matrices carrying IL-15SA + CpG or two injections
of IL-15SA-carrying gels are as effective as DC-carrying gels in controlling tumor growth
(A) Tumor growth curves from individual mice shown for an independent experiment
comparing untreated tumors vs. mice injected twice (day 14 and day 21) with alginate carrying
IL-15SA. (B) Mean tumor size vs. time for mice receiving 3×104 B16-ova cells s.c. and left
untreated (○) or receiving a single peritumoral injection on day 14 of alginate carrying
2×106 DCs and 36.7 μg IL-15SA (■, P = 0.04), a single injection of alginate carrying IL-15SA
and 80 μg CpG (✖, P = 0.22), or receiving two injections of alginate carrying 36.7 μg IL-15SA
on days 14 and 21 (△, P = 0.04) (n = 10 per group). (C) Survival of mice left untreated (○) or
receiving a single peritumoral injection of alginate carrying IL-15SA and 80 μg CpG (✖), or
receiving two injections of alginate each carrying 36.7 μg IL-15SA on days 14 and 21 (△).
Data shown representative from 1 of 2 independent experiments. (D, E) Mice receiving
3×104 B16F10 tumor cells s.c. were left untreated (○) or were treated on days 11 and 18 with
alginate gels carrying 36.7 μg IL-15SA (△). P-values relative to untreated controls. Data shown
representative from 1 of 2 independent experiments. (error bars: s.e.m)
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Fig. 6. Immune cell accumulation in peritumoral alginate ECMs correlates with accumulation in
tumors
Established B16-ova tumors were treated with 2 injections of IL-15SA-loaded alginate as in
Fig. 5. Gels and tumors were analyzed by flow cytometry and shown are pooled results for
gels/tumors taken from the same mice on d28: (A) CD4+TCR+ and CD8+TCR+ T-cell
frequencies; (B) CD11c+ cells; (C) NK1.1+ cells. (D) Correlation of T cell and NK cell
infiltration of tumors with final tumor size. Shown is one of 3 independent experiments.
Hori et al. Page 19
Biomaterials. Author manuscript; available in PMC 2010 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 7. NK cells and DCs accumulate at tumor sites treated with IL-15SA/alginate gels, while
frequencies of Tregs in the tumor are reduced
B16-ova-tumor-bearing mice were left untreated or received two injections of IL-15SA-loaded
alginate on days 14 and 21 as in Fig. 5. On day 28, tumors and gels were recovered and
frequencies of CD4+foxp3+ cells, CD11c+ DCs, and NK1.1+ natural killer cells were
determined. (A) Representative flow cytometry plots showing CD4 and foxp3 stainings. Bar
graphs: the frequencies of CD4+foxp3+ cells out of all live lymphocytes (A) and those out of
all T cells (B); the frequencies of CD11c+ DCs (D), and NK1.1+ natural killer cells in tumors
(F). (E) Numbers of gel-infiltrating host DCs that were GFP+, suggesting active acquisition of
tumor antigen in the peritumoral matrices. (error bars: s.e.m.)
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